• Nano-Embedded In-Microparticles (NEMs) encapsulate RNA-loaded lipid nanoparticles (LNPs) within a protective excipient matrix.
• NEM technology enables pulmonary administration of RNA therapeutics via Dry Powder Inhalers (DPIs).
• The dry powder formulation offers improved stability, simplifying storage, logistics, and global distribution, facilitating the widespread use of RNA therapeutics for respiratory conditions.

Respiratory RNA therapeutics face significant challenges in achieving regulatory approval. Currently, RNA therapies for pulmonary diseases in clinical trials are delivered either via nebulization of fluid suspensions or intravenous (IV) injection, both of which present limitations related to their administration methods. In response, we introduce Nano-Embedded in-Microparticle (NEM) technology, a novel approach designed to overcome these barriers. Our technology encapsulates RNA-loaded lipid nanoparticles (LNPs) within an excipient matrix, providing robust protection against external factors. The resulting dry powder formulation can be administered using established Dry Powder Inhalers (DPIs). Our approach offers localized, efficient, and discreet administration suitable for public and social settings. Additionally, the enhanced stability of the dry powder formulation simplifies storage, logistics, and global distribution, addressing a critical need for the widespread deployment of RNA therapeutics for pulmonary conditions.

Benjamin Winkeljann

Group Leader (LMU), CEO (RNhale)

Ludwig-Maximilians-University (LMU) Munich & RNhale GmbH